NCT06493253View on ClinicalTrials.gov

Digital Pathology and AI for Liver Outcomes in MASLD (DPAILO-2)

Not yet recruitingOBSERVATIONAL
Enrollment

1,700

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

January 1, 2026

Study Completion Date

March 1, 2026

Conditions
Metabolic Dysfunction-associated Steatotic Liver Disease
Interventions
DIAGNOSTIC_TEST

Digital Pathology FibroNest Phenotypic Fibrosis Composite Score (Ph-FCS)

Biomarker name: FibroNest Phenotypic Fibrosis Composite Score Acronym: FibroNest Ph- FCS Type of Biomarker: Histologic based, Digital, Quantitative Image Analysis, Imaging modality Definition: A quantitative, normalized (no unit) and continuous composite

Trial Locations (1)

23284

Virginia Commonwealth University, Richmond

Sponsors

Lead Sponsor

PharmaNest, Inc
All Listed Sponsors
collaborator

Nonalcoholic Steatohepatitis Clinical Research Network (NASH)

UNKNOWN

collaborator

Virginia Commonwealth University

OTHER

lead

PharmaNest, Inc

INDUSTRY